Methods for treatment of diabetes using peptide analogues of insulin
AssigneeNeurocrine Biosciences, Inc.
InventorsAmitabh Gaur, Nicholas Ling, Paul Conlon
Life of this patent
Estimating the term…
Abstract
The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.
Claims21
1-27. (canceled)
A peptide analogue comprising residues 9 to 23 of human insulin B chain, wherein the peptide analogue differs in sequence from native human insulin B chain residues 9 to 23 due to substitutions at between 1 and 4 amino acid positions, and wherein one substitution occurs at residue 19.
Dependencies are inferred from the claim text.